2Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med, 2006, 355 : 1345-1356.
3Ryu JH, Moss J, Beck G J, et al. The NHLBI lymphangioleiomyomatosis registry. Characteristcs of 230 patients at enrollment. Am J Respir Crit Care Med, 2006, 173: 105-111.
4Young LR, Inoue Y, McCormack FX. Diagnostic Potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med, 2008, 358: 199-200.
5Crooks DM, Pacheco-Rodriguez G, DeCastro RM, et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci USA, 2004, 101: 17462-17467.
6Schiavina M, Contini P, Fabiani A, et al. Efficacy of hormonal manipulation in lymphangioleiomyomatosis. A 20-year-experience in 36 patients. Sarcoidosis Vasc Diffuse Lung Dis, 2007, 24 : 39- 50.
7Taveira-DaSilva AM, Stylianou MP, Hedin C J, et al. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest, 2004, 126 : 1867-1874.
8Harari S, Cassandro R, Chiodini J, et al. Effects of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis. Chest, 2008, 133:448-454.
9Juvet SC, McConnack FX, Kwiatkowski DJ, et al. Molecular pathogenesis of lymphangioleiomyomatosis. Lessons learned from orphans. Am J Respir Cell Mol Biol, 2007, 36: 398-408.
10Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med, 2008, 358: 140-151.
